Fox Chase Cancer Center News

PHILADELPHIA (December 2, 2022)—Fox Chase Cancer Center physicians Hossein Borghaei, DO, MS, and Elizabeth Plimack, MD, MS, have been named to the 2022 list of Highly Cited Researchers by Clarivate, an information and analytics firm focused on research.

PHILADELPHIA (December 2, 2022)—Fox Chase Cancer Center’s Richard J. Bleicher, MD, FACS, a professor in the Department of Surgical Oncology and leader of the Breast Cancer Program, was recently inducted as a fellow into the Philadelphia Academy of Surgery.

PHILADELPHIA (December 2, 2022)—Fox Chase Cancer Center’s Allison A. Aggon, DO, FACOS, an associate professor in the Department of Surgical Oncology, was recently inducted as a fellow into the Philadelphia Academy of Surgery.

PHILADELPHIA (November 18, 2022)—Genetically targeted therapy can make treatment for lung cancer much more effective, but testing to identify specific gene fusions involved in the disease remains a challenge. However, a new study by researchers at Fox Chase Cancer Center demonstrates that RNA next-generation sequencing (RNA-NGS) can offer results that are more accurate and comprehensive while using smaller tissue samples.

PHILADELPHIA (November 17, 2022)—Fox Chase Cancer Center and Oryzon Genomics S.A. will work together to test the safety and efficacy of the drug iadademstat in patients with pulmonary and extrapulmonary neuroendocrine carcinomas (NECs), which are rare and heterogeneous cancers arising from neuroendocrine cells, and small cell lung cancer (SCLC).

Fox Chase Cancer Center recently welcomed Senator Jimmy Dillon to take a tour and learn more about Fox Chase, its mission, and its accomplishments, including two Nobel Prizes. Much of that history is outlined in an exhibit in the Center’s Young Pavilion, which Dillon visited.

PHILADELPHIA (November 17, 2022)—It’s long been known that DNA damage caused by environmental triggers, as well as other sources of oxidative stress, contribute to the development and progression of a wide variety of cancers. Now a new study by a Fox Chase Cancer Center scientist provides new insight into how an enzyme called apurinic/apyrimidinic 1 (APE1) repairs this damage.

PHILADELPHIA (November 15, 2022)—Two Fox Chase Cancer Center researchers have received $75,000 grants from the Kidney Cancer Association (KCA) to pursue studies that could improve kidney cancer treatment and care.